The United States of America, As Represented by the Secretary, Department of Health and Human Services

Oxxon Therapeutics Limited

Isis Innovation Limited

Oxxon Pharmaccines Ltd.

Geoffrey L Smith

Bernard Moss

Sarah C Gilbert

Andrew James McMichael

Tomas Hanke

Michael Mackett

Magdalena Plebanski

Adrian V S Hill

Tom Blanchard

Aylwin Ng

Jörg Schneider

J&ouml;rg Schneider

New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumor antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.

Methods and reagents for immunization which generate a CD8 T cell immune response

New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.

Methods and reagents that generate a CD8 T cell immune response

Use for novel chemokine-binding protein designated A41L, and chemokine-binding fragments thereof, for the treatment of conditions such as inflammation. The A41L protein binds to chemokines in the CXC group.

Recombinant poxvirus

Recombinant poxviruses, such as vaccinia, are provided that comprises a segment comprised of (A) a first DNA sequence encoding a polypeptide that is foreign to poxvirus and (B) a poxvirus transcriptional regulatory sequence, wherein (i) said transcriptional regulatory sequence is adjacent to and exerts transcriptional control over said first DNA sequence and (ii) said segment is positioned within a nonessential genomic region of said recombinant poxvirus. Vaccines, carriers, cells, and media comprising recombinant poxviruses, and methods of immunization with recombinant poxviruses also are provided.

Methods of immunization using recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences

Recombinant poxviruses, such as vaccinia, are provided that comprises a segment comprised of (A) a first DNA sequence encoding a polypeptide that is foreign to poxvirus and (B) a poxvirus transcriptional regulatory sequence, wherein (i) said transcriptional regulatory sequence is adjacent to and exerts transcriptional control over said first DNA sequence and (ii) said segment is positioned within a nonessential genomic region of said recombinant poxvirus. Vaccines, carriers, cells, and media comprising recombinant poxviruses, and methods of immunization with recombinant poxviruses, also are provided.

Compositions containing recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences

Recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences

Methods and reagents for vaccination which generate a CD8 T cell immune response

Use for novel chemokine-binding protein designated A41L, and chemokine-binding fragments thereof, for the treatment of conditions such as inflammation. The A41L protein beinds to chemokines in the CXC group.

Soluble vaccinia virus protein that binds chemokines

Growing community of inventors

Oxford, United Kingdom

Geoffrey L Smith